Abstract: A regeneratable polymer-supported Pd(O) catalytic deblocking process using a regeneratable polymer-supported Pd(O) catalyst in a biphasic system deblocks various allyl-protected ester, carbonates, carbamates and cinnamyl esters.
Type:
Grant
Filed:
November 7, 1990
Date of Patent:
June 23, 1992
Assignee:
Merck & Co., Inc.
Inventors:
David M. Tschaen, F. Edward Roberts, Thomas R. Verhoeven
Abstract: A process is described for the stereochemically controlled synthesis of intermediates useful in producing 1-betamethylcarbapenem antibiotic intermediates involving reacting a beta lactam with a chiral thia- or oxazolidinone enolate to preferentially produce a beta-methyl intermediate which can be transformed into a carbapenem antibiotic.
Type:
Grant
Filed:
July 11, 1990
Date of Patent:
April 14, 1992
Assignee:
Merck & Co., Inc.
Inventors:
Thomas N. Salzmann, Lelia M. Fuentes, Ichiro Shinkai
Abstract: New 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids are described which display antibacterial activity and potentiate carbapenem antibiotics.
Type:
Grant
Filed:
June 21, 1990
Date of Patent:
March 24, 1992
Assignee:
Merck & Co., Inc.
Inventors:
William H. Parsons, Arthur A. Patchett, William R. Schoen, Masao Taniguchi
Abstract: Compounds of the formula: ##STR1## where R.sup.2 contains certain aryls or heteroaryls are effective leukotriene inhibitors.
Type:
Grant
Filed:
March 12, 1990
Date of Patent:
February 25, 1992
Assignee:
Merck Frosst Canada, Inc.
Inventors:
Patrice C. Belanger, Claude Dufresne, Brian Fitzsimmons, deceased, Maryann Fitzsimmons, Heir, Yvan Guindon, Cheuk K. Lau, Joshua Rokach, John Schiegetz, Michel Therien, Robert N. Young
Abstract: Provided are new antibacterial spirocyclic 6-amido carbapenems of the formula: ##STR1## wherein: R.sup.1 is hydrogen, C.sub.1-8 substituted or unsubstituted alkyl or C.sub.6-10 substituted or unsubstituted aryl;R.sup.2 is hydrogen, C.sub.1-8 substituted or unsubstituted alkyl or C.sub.2-8 substituted or unsubstituted acyl;R.sup.3 is hydrogen, C.sub.1-8 substituted or unsubstituted thioalkyl or C.sub.6-10 substituted or unsubstituted thioaryl, or 5 or 6 membered substituted or unsubstituted thioheteroaryl; andR.sup.4 is hydrogen, pharmaceutically acceptable alkali metal salt or biolabile ester,and a process for their synthesis through novel intermediates.
Type:
Grant
Filed:
August 30, 1990
Date of Patent:
October 8, 1991
Assignee:
Merck & Co., Inc.
Inventors:
Mark L. Greenlee, Frank P. DiNinno, Thomas N. Salzmann
Abstract: Carbapenems of the formula ##STR1## wherein either the 2-fluoren-9-one or 3-fluoren-9-one is attached at the 2-position of the carbapenem are useful antibacterial agents.
Type:
Grant
Filed:
August 1, 1990
Date of Patent:
July 23, 1991
Assignee:
Merck & Co., Inc.
Inventors:
Mark L. Greenlee, Frank P. DiNinno, Lovji D. Cama, James V. Heck
Abstract: Carbapenems of the formula ##STR1## wherein either the 2-fluoren-9-one or 3-fluoren-9-one is attached at the 2-position of the carbapenem are useful antibacterial agents.
Type:
Grant
Filed:
August 1, 1990
Date of Patent:
June 18, 1991
Assignee:
Merck & Co., Inc.
Inventors:
Mark L. Greenlee, Frank P. DiNinno, Lovji D. Cama, James V. Heck
Abstract: Described is a new process for producing new 2-substituted alkyl-3-carboxycarbapenems, involving condensation of a 2-oxocarbapenam-3-carboxylic ester with a stabilized ylide followed by ester deblocking. The resulting carbapenem compounds, which are not readily available from other known synthetic routes, show interesting antibacterial activity.
Abstract: Disclosed are pharmaceutical compositions for enhancing human host resistance against opportunistic infection in an individual immunocompromised by an AIDS-related virus, consisting essentially of an anti-viral, anti-AIDS drug selected from the group consisting of ansamycin, ribavirin, dideoxycitidine, HPA-23, AL-721, foscarnet, and azidothymidine and a glycolipid compound consisting essentially of the formula: ##STR1## where: R.sup.1 is .alpha. or .beta.-D-1-thiomannopyranoside, .alpha. or .beta.-L-1-thiofucopyranoside.
Type:
Grant
Filed:
June 21, 1989
Date of Patent:
May 28, 1991
Assignee:
Merck & Co., Inc.
Inventors:
Philippe L. Durette, William K. Hagmann, Mitree M. Ponpipom
Abstract: Virginiamycin M.sub.1 having the Formula: ##STR1## and virginiamycin M.sub.1 analogs having the Formulae I-IV: ##STR2## Virginiamycin M.sub.1 and the analogs I-IV are antagonists of cholecystokinin (CCK) and gastrin. Cholecystokinin antagonists are useful as analgesics and in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems in animals, especially humans. Gastrin antagonists are useful in blocking the receptors for gastrin in humans and may function as agents for the treatment of ulcers, tumors or other gastrointestinal disorders. The compounds of Formulae I-IV are antibiotics and are useful as antimicrobial agents in animals including man and are useful as food additives to promote feed utilization in animals. Virginiamycin M.sub.1 and the analogs of Formula I, III and IV are produced by the controlled aerobic fermentation of a strain of Streptomyces olivaceus, ATCC No. 53527, while the analog of Formula II is produced by chemical synthesis.
Type:
Grant
Filed:
October 26, 1989
Date of Patent:
April 9, 1991
Assignee:
Merck & Co., Inc.
Inventors:
Yiu-kuen T. Lam, Otto D. Hensens, Raymond S. Chang, Cheryl D. Schwartz, Deborah L. Zink
Abstract: Disclosed are steroidal derivatives of glycolipids, in which steroids are bridged, via a medium length hydrocarbon chain, to 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses in combination with an anti-AIDS drug, that protect an immunocomprimised hot, particularly resulting from an AIDS-related virus, against opportunistic infection.
Type:
Grant
Filed:
July 10, 1989
Date of Patent:
November 13, 1990
Assignee:
Merck & Co., Inc.
Inventors:
Philippe L. Durette, William K. Hagmann, Mitree M. Ponpipom